{
  "release_id": "fc5a600ec7387e71",
  "id": "maternal:guideline-uspstf-2023-folic-acid",
  "owner": "maternal",
  "kind": "guideline",
  "slug": "guideline-uspstf-2023-folic-acid",
  "name": "USPSTF 2023: folic acid supplementation to prevent neural tube defects (reaffirmation)",
  "aliases": [],
  "atlases": [
    "maternal"
  ],
  "summary_plain": "A 2023 statement from the US Preventive Services Task Force (USPSTF) that reaffirms its advice that everyone planning a pregnancy, or who could become pregnant, should take a daily folic acid supplement containing 0.4 to 0.8 mg.",
  "summary_technical": "USPSTF reaffirmation recommendation statement, JAMA 2023, volume 330, issue 5 (PubMed issue date 2023-08-01). The A recommendation and the task force wording of certainty are recorded as a claim on the folic acid page. The linked evidence report (PMID 37526714) is cited from the folic acid and neural tube defect pages. Whether a later edition exists was not checked. The guideline's source is the USPSTF final recommendation statement page, which gives the statement date that the recommendation decisions use; the JAMA statement stays cited in the claims.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-10-14",
  "last_evidence_check": "2026-10-14",
  "next_review_due": null,
  "identifiers": [],
  "navigation": {
    "maternal": {
      "life-stage": [
        "preconception",
        "pregnancy"
      ],
      "care-area": [
        "preconception-health"
      ]
    }
  },
  "payload": {
    "source": "maternal:uspstf-folic-acid-2023",
    "issuers": [
      "core:uspstf"
    ],
    "edition": "USPSTF final recommendation statement, as shown on its page; also published as: Reaffirmation recommendation statement, JAMA 2023;330(5)",
    "published": "2023-08-01",
    "planned_update": null,
    "status": "not_checked",
    "scope": "Persons who are planning to or could become pregnant",
    "plain_interpretation": null
  },
  "content_digest": "102f831a09c08c8c8040dbd4af42371eee12511a9befe161717139fd14511f4c",
  "review": {
    "content_digest": "102f831a09c08c8c8040dbd4af42371eee12511a9befe161717139fd14511f4c",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "authored_by",
        "label": "Issued by the US Preventive Services Task Force",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "core:uspstf",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "maternal:pubmed-37526713-2026-10-14",
          "locator": "AuthorList, collective name"
        },
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "guidelines/guideline-uspstf-2023-folic-acid/",
  "context_path": "api/v1/context/maternal--guideline-uspstf-2023-folic-acid.md"
}